Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec 4:8:3621-7.
doi: 10.2147/OTT.S91347. eCollection 2015.

Long-term administration of high doses of transdermal buprenorphine in cancer patients with severe neuropathic pain

Wojciech Leppert  1 , Grzegorz Kowalski  1
Affiliations

Long-term administration of high doses of transdermal buprenorphine in cancer patients with severe neuropathic pain

Wojciech Leppert et al. Onco Targets Ther. .

Abstract

Background: Buprenorphine is often administered by the transdermal route (transdermal buprenorphine [TB]) in cancer patients with severe neuropathic pain. However, high doses of TB of 140 µg/h are rarely used.

Patients and methods: Three cancer patients with severe neuropathic Numeric Rating Scale (NRS) pain scores of 8-10 who were successfully treated with high doses of TB up to 140 µg/h along with other opioids and adjuvant analgesics.

Results: TB was administered for a long period of follow-up (9 months to 4 years, including 34-261 days of treatment with the dose of 140 µg/h), which allowed achievement of satisfactory analgesia (NRS 3-5) and good treatment tolerance. In all three patients, TB dose was gradually titrated from 35 to 140 µg/h, and all patients used morphine at least for some time for breakthrough and background pain management along with adjuvant analgesics. Two patients continued the treatment with TB until the end of life, and one patient is still receiving the treatment.

Conclusion: TB at doses of up to 140 µg/h in cancer patients with severe neuropathic pain seems to be effective and safe in combination with other opioids and with adjuvant analgesics, and may significantly improve patients' quality of life. Clinical studies may explore higher than maximal 140 µg/h TB doses recommended by a manufacturer, and also in combination with other opioids and adjuvant analgesics.

Keywords: adverse effects; analgesia; cancer; neuropathic pain; transdermal buprenorphine; treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pain intensity and TB doses in a patient diagnosed with chondrosarcoma of the sacral bone. Abbreviations: NRS, Numeric Rating Scale (0 – no pain, 10 – the most severe pain intensity); TB, transdermal buprenorphine; MF, morphine.
Figure 2
Figure 2
Pain intensity and TB doses in a patient diagnosed with thyroid carcinoma and bone metastases. Notes: *Palliative radiotherapy for lumbar spine metastases. #1, 2, 3, and 4 refer to the weeks of each month listed. Abbreviations: NRS, Numeric Rating Scale (0 – no pain, 10 – the most severe pain intensity); TB, transdermal buprenorphine; MF, morphine; IV, intravenous; PRN, pro re nata (as needed).
Figure 3
Figure 3
Pain intensity and TB doses in a patient diagnosed with rectal carcinoma and sacral bone infiltration. Notes: *Pathological fracture of the left femur bone; surgery and a stay in hospital until May 2014. #1, 2, 3, and 4 refer to the weeks of each month listed. Abbreviations: NRS, Numeric Rating Scale (0 – no pain, 10 – the most severe pain intensity); TB, transdermal buprenorphine; MF, morphine; SC, subcutaneous.
See this image and copyright information in PMC

References

    1. Sittl R. Transdermal buprenorphine in cancer pain and palliative care. Palliat Med. 2006;20(Suppl 1):s25–s30. - PubMed
    1. Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, ran-domized, double-blind, placebo-controlled trial. Clin Ther. 2003;25:150–168. - PubMed
    1. Kusnik S, Likar R, Sittl R. Transdermal buprenorphine in chronic pain: indications and clinical experience. Expert Rev Clin Pharmacol. 2008;1:729–736. - PubMed
    1. Christoph T, Kögel B, Schiene K, Méen M, De Vry J, Friderichs E. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol. 2005;507:87–98. - PubMed
    1. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13:e58–e68. - PubMed